

Attorney Docket No: 20200/2092 (Serial No.: 09/889,802)

Inventor: Kreutzer, et al.

Filed: September 17, 2001

Third Preliminary Amendment

Page 4

236. (New) The mammalian cell of claim 232, wherein the RNA transcript is a primary or a processed RNA

237. (New) The mammalian cell of claim 232, wherein the dsRNA comprises a linker between the two RNA strands.

238. (New) The mammalian cell of claim 232, wherein the linker is a polyethylene glycol linker.


REMARKS

Applicants submit that no new fees are believed to be required for newly added claims 221-238, but hereby authorize the Commissioner to charge any additional claim fees to Deposit Account No. 16-0085, Reference No. 20200/2092.

Applicants respectfully request entry of the above amendments.

Date: February 5, 2003

Respectfully submitted,



Name: Barbara A. Gyure
Registration No.: 34,614
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100

Attorney Docket N : 20200/2092 (Serial No.:09/889,802)

Inventor: Kreutzer, et al.

Filed: September 17, 2001

Third Preliminary Amendment

Page i

MARKED-UP VERSION OF AMENDMENTS:

Specification Amendments Under 37 C.F.R. § 1.121(b)(1)(iii)

Please replace the title of the application with the title below, which is marked up by way of bracketing and underlining to show the changes relative to the previous version of the title:

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A DEFINED

GENE

[METHOD AND MEDICAMENT FOR INHIBITING THE EXPRESSION OF A DEFINED
GENE]